Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07142811 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Apr 2031 to Jul 2030
    • Eligibility criteria revised
    • Site details revised at 31 of 31 sites
    v4
  2. Study sites: 26 to 31v3
  3. Study sites: 12 to 26v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
Trial Details
NCT Number NCT07142811
Lead Sponsor Vir Biotechnology, Inc.
Conditions
(from sponsor)		 Viral Hepatitis
Related terms Digestive System Diseases, Hepatitis, Hepatitis D, Hepatitis D, Chronic, Liver Diseases
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov